Dermira Inc (NASDAQ:DERM) shares were down 6.2% during mid-day trading on Wednesday . The company traded as low as $11.01 and last traded at $11.13. Approximately 1,841,575 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 1,880,821 shares. The stock had previously closed at $11.87.
A number of research analysts recently issued reports on DERM shares. BidaskClub cut Dermira from a “buy” rating to a “hold” rating in a report on Friday, December 28th. Cantor Fitzgerald set a $20.00 price target on Dermira and gave the company a “buy” rating in a report on Friday, December 28th. ValuEngine cut Dermira from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Zacks Investment Research raised Dermira from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a report on Thursday, January 10th. Finally, Raymond James raised Dermira from an “underperform” rating to a “market perform” rating and set a $6.71 price objective for the company in a report on Thursday, January 17th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. Dermira currently has a consensus rating of “Buy” and an average price target of $17.36.
The firm has a market capitalization of $615.99 million, a price-to-earnings ratio of -2.12 and a beta of 1.45. The company has a debt-to-equity ratio of 5.21, a current ratio of 8.70 and a quick ratio of 8.48.
Dermira (NASDAQ:DERM) last announced its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.75) by $0.05. Dermira had a negative return on equity of 309.23% and a negative net margin of 523.25%. As a group, equities analysts anticipate that Dermira Inc will post -5.25 EPS for the current year.
In other Dermira news, insider Eugene A. Bauer sold 35,000 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $15.00, for a total transaction of $525,000.00. Following the completion of the sale, the insider now directly owns 43,900 shares of the company’s stock, valued at approximately $658,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.80% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in shares of Dermira by 2,500.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 10,400 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 10,000 shares during the last quarter. MetLife Investment Advisors LLC increased its stake in shares of Dermira by 55.6% in the 3rd quarter. MetLife Investment Advisors LLC now owns 28,224 shares of the biopharmaceutical company’s stock valued at $308,000 after acquiring an additional 10,085 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Dermira by 356.7% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,912 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 10,085 shares during the last quarter. Marshall Wace North America L.P. bought a new stake in shares of Dermira in the 3rd quarter valued at about $128,000. Finally, Nomura Holdings Inc. increased its stake in shares of Dermira by 18.5% in the 4th quarter. Nomura Holdings Inc. now owns 75,696 shares of the biopharmaceutical company’s stock valued at $544,000 after acquiring an additional 11,836 shares during the last quarter. 69.08% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Zolmax and is the sole property of of Zolmax. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://zolmax.com/investing/dermira-derm-trading-down-6-2/3042810.html.
Dermira Company Profile (NASDAQ:DERM)
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Featured Article: What is a Reverse Stock Split?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.